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Summary When assessing the value of a particular treatment, it is important to consider the impact it may have on the quality of life of those
being treated. This is particularly so for cancer patients, whose life expectancy may be short. Patients with advanced colorectal cancer who
participated in two international comparative studies of raltitrexed ('Tomudex') vs standard 5-fluorouracil (5-FU) plus leucovorin (LV)
completed previously validated quality-of-life questionnaires (EORTC questionnaire, EuroQol and Rotterdam Symptom Check List) at various
times during the studies. Early statistically significant advantages of raltitrexed vs 5-FU plus LV on quality of life were observed at week 2 in
five of eight of the EuroQol and three of four of the Rotterdam Symptom Check List dimensions. Such advantages were not observed using
the EORTC questionnaire, which was not completed until week 12. The necessary dose delays and different dose schedules made it difficult
in these studies to compare the impact on quality of life of the two treatments. It may be that performance status, effect on disease-related
symptoms and the incidence of toxicity are the most important indications of a patient's quality of life.
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EORTC core instrument
Randomized trials have shown that chemotherapy improves
survival and quality of life in advanced colorectal cancer
(Nordic Gastrointestinal Tumor Adjuvant Therapy Group, 1992;
Scheithauer et al, 1993; Allen-Mersh et al, 1994; Glimelius et al,
1994). Scheithauer et al (1993) showed a median survival of 5
months for best supportive care vs 11 months for patients random-
ized to receive chemotherapy (P = 0.006). In addition, there was a
trend towards improved quality of life in patients with abnormal
scores (at least one global or subgrouping score below normal) at
baseline. In another randomized trial, the Nordic Gastrointestinal
Tumor Adjuvant Therapy Group (1992) assessed the value of
immediate ordelayed chemotherapy in 183 patients with advanced
asymptomatic colorectal cancer. They showed that immediate
chemotherapy increased survival [from 9 to 14 months (median
values)] and time without symptoms (from 2 to 10 months)
compared with delayed chemotherapy. Allen-Mersh et al (1994)
randomized 100 patients with liver metastases from colorectal
cancer to receive hepatic arterial infusion (HAI) with fluoxuridine
or symptomatic therapy. Only 10 of49 patients in the latter group
received any systemic chemotherapy, the majority being termi-
nally ill when symptoms did occur. The patients in the HAI group
had increased survival of normal quality (i.e. with normal
symptom scores) for physical and psychological symptoms
(P = 0.04) compared with the group receiving conventional pallia-
tion. Overall survival was also improved by HAI (median 405 vs
226 days; P = 0.03). Glimelius et al (1994) randomized patients
with metastatic gastrointestinal carcinoma (18 gastric, 22 pan-
creatobiliary and 21 colorectal cancer patients) to chemotherapy
plus best supportive care vs best supportive care alone. Overall
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survival was significantly longer in the chemotherapy group
than in the best supportive care group (median 9 vs 4 months;
P < 0.05), and twice as many patients receiving chemotherapy
compared with those in the best supportive care-alone group (58%
vs 29%; P < 0.05) had favourable quality-of-life outcomes.
Despite this evidence, many patients with metastatic colorectal
cancer are not being considered for palliative chemotherapy. A
recent survey involving specialists from five countries showed that
referral patterns were inconsistent (International Working Group
in Colorectal Cancer, 1997). Reasons for non-referral were based
on clinicians' assessment that chemotherapy would adversely
affect quality of life. However, few of those clinicians had used
quality-of-life assessments during their routine work. Clinicians'
views of the value of chemotherapy differ according to their
specialist role, and clinicians are less likely than patients to accept
palliative chemotherapy (Slevin et al, 1990; Bremnes et al, 1995).
Evidence based on patient-rated quality oflife will be the key to
the wider acceptance of the value of palliative chemotherapy by
clinicians and purchasers ofhealthcare. This trend is already being
shown by the inclusion by major study groups (NCI, MRC,
EORTC) ofquality-of-life end points in clinical trials, and by the
increasing requirement from regulatory authorities for quality-of-
life data for approval ofnew anti-cancer therapies (Nayfield et al,
1992; Taylor et al, 1994; Fayers et al, 1997).
This paper describes quality-of-life assessments in two phase III
trials comparing raltitrexed ('Tomudex') with regimens based on
5-fluorouracil (5-FU) modulated with leucovorin (LV). Raltitrexed
is athymidylate synthase inhibitorthat, unlike 5-FU, has no effects
on RNA and protein synthesis. It was hypothesized that it would
have similarefficacy but fewer side-effects than 5-FU and that this
would translate into improved quality oflife.
'Tomudex' is a trademark, the property ofZeneca.
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Figure 1 Pattern of quality-of-life questionnaire completion in relation to treatment cycle in study 3. 5-FU, 5-fluorouracil; LV, leucovorin
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Figure 2 Pattern of quality-of-life questionnaire completion in relation to treatment cycle in study 12. 5-FU, 5-fluorouracil; LV, leucovorin
PATIENTS AND METHODS
Patients with advanced colorectal cancer were treated in two
multicentre, international phase III trials of raltitrexed vs 5-FU
with either low- or high-dose LV. These trials assessed tumour
response, survival and palliation in addition to quality of life. The
quality-of-life tools used had to be applicable to cancer patients,
properly validated and available for international use (i.e. vali-
dated in several languages). The first study (study 3) (Cunningham
et al, 1996; Kerr, 1997) used the early version of the EORTC
(European Organisation of Research and Treatment of Cancer)
core instrument (the colorectal cancer add-on module was not
available at the time of study commencement). This instrument
has 30 questions that cover the five functional scales (physical,
role, cognitive, emotional and social), three symptom scales
(fatigue, pain, and nausea and vomiting) and a global health
quality-of-life scale. The remaining single items are dyspnoea,
appetite loss, sleep disturbance, constipation and diarrhoea.
At the time the study was designed, the EORTC core instrument
was the only tool validated in languages other than English.
Questionnaires were completed before randomization and every
12 weeks thereafter. The questionnaire reflected the patient's
symptoms over the previous 7 days and was completed before
physician assessment. The results from the first study (study 3)
showed no significant differences between treatments (see Results
section). It was felt that the quality-of-life questionnaire did not
reflect the toxicity ofthe treatments (it did not include diarrhoea or
mucositis) and was not completed frequently enough. Different
tools were therefore chosen for further work.
In the second study (study 12) (Harper, 1997; Kerr et al, 1997)
the quality-of-life tools used were the Rotterdam Symptom
Checklist (RSCL) (De Haes et al, 1983; De Haes et al, 1990) and
EuroQol (Williams, 1990). These questionnaires were completed
atbaseline, at weeks 2, 5 and 10, and every 5 weeks thereafter. The
RSCL consists of 38 items and an overall quality-of-life question.
These are divided into physical symptom distress (23 items),
psychological symptom distress (seven items) and activity level
(eight items). We divided the physical symptom score into disease-
related symptoms (seven items), toxicity-related symptoms (11
items) and disease- or toxicity-related symptoms (five items). All
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Table 1 RSCL questionnaire completion rates in study 12 for raltitrexed (R) and 5-fluorouracil (5-FU) plus leucovorin (LV)
Week
0 2 5 10 15 20 25
R 5-FU+LV R 5-FU+LV R 5-FU+LV R 5-FU+LV R 5-FU+LV R 5-FU+LV R 5-FU+LV
No. available 227 218 169 155 193 179 131 163 90 115 63 89 51 62
Total no. of patients 247 248 245 244 237 240 190 216 135 161 99 118 77 103
Completion rate (%) 92 88 69 64 81 75 69 75 67 71 64 75 66 60
38 items are given a score of 0 to 3 and the overall quality-of-life
score is from 1 to 7. The EuroQol questionnaire consists of five
dimensions, each consisting of a single question (mobility, self-
care, usual activities, pain/discomfort and anxiety/depression), a
general health question and a health state visual analogue scale.
RESULTS
Study 3
Study 3 compared 5-FU plus low-dose LV with raltitrexed 3 mg m-2
every 3 weeks. The 5-FU regimen was given every 4 weeks for
three courses, then every 5 weeks. The treatment pattern in relation
to the quality-of-life questionnaire administration is shown in
Figure 1. Baseline quality-of-life forms were available for 216 out
of 223 (97%) patients allocated to raltitrexed and 208 out of 216
(94%) to 5-FU + LV. Attrition due to withdrawal from study
occurred by week 12, but 118 out of 119 (99%) raltitrexed and 105
out of 110 (95%) patients allocated to 5-FU + LV who were still on
study had quality-of-life forms available for analysis. There were
different toxicity patterns, and dosage reductions at cycle 2 were
made according to protocol in 33% of 5-FU + LV and 5% of
raltitrexed patients. The 5-FU + LV regimen caused more grade 3
and4haematological (haemoglobin, white blood cells, platelets and
neutrophils) and non-haematological (diarrhoea, rash and
mucositis) toxicity in the first two cycles (P < 0.0001) (cycle 1:
raltitrexed 5.9% vs 5-FU + LV 35.9%; cycle 2: raltitrexed 7.7% vs
5-FU + LV 27.4%). Overall, raltitrexed caused less grade 3 or 4
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leucopenia, mucositis, diarrhoea and alopecia than 5-FU but more
anaemia and asymptomatic increases in transaminases, nausea and
vomiting, and fatigue. Results from study 3 showed no significant
differences in quality oflife between the two treatments. It was felt
that the quality-of-life questionnaire did not reflect the toxicity of
treatments (the first version did not include diarrhoea or
mucositis), and it was not completed frequently enough. Patients
on 5-FU + LV had significantly more toxicity and consequent
dosage reductions.
For the EORTC core instrument, aproportional odds model was
used for the 12-, 24-, and 36-week assessments. Missing values
were dealt with in the following way: if data existed for at least
50% of the items in a dimension for a particular patient, the total
score for that dimension was scaled up proportionately and
assigned to the appropriate ordered category. There were improve-
ments in emotional function, sleep and constipation in both
groups, and no difference in global quality oflife between the two
groups. For the symptom scales, there was a statistically signifi-
cant difference between raltitrexed and 5-FU + LV (in favour of5-
FU + LV) for nausea and vomiting at week 12 (odds ratio 2.20,
95% confidence interval 1.29-3.77, P = 0.0041). A gain in body-
weight of at least 5% was seen in 15.7% of patients in the
5-FU + LV group and in 16.6% of those receiving raltitrexed.
More than half the patients recruited in each group had a perfor-
mance status score ofone ormore atbaseline, andimproved scores
were seen after treatment in 36.4% of raltitrexed patients and
29.7% of5-FU + LV patients (P = 0.32).
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Figure 3 Changes relative to baseline in quality-of-life dimensions of EuroQol in study 12. 5-FU, 5-fluorouracil; LV, leucovorin
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Figure 5 Predefinedtoxicity-related symptoms in study 12. Bars represent
changes from baseline in mean toxicity scores. Scores increase with toxicity
Study 12
Study 12 compared 5-FUI + high-dose LV with raltitrexed
3 mg m-2 every 3 weeks. 5-FU was administered every 4 weeks in
this study. The treatment pattern in relation to quality-of-life
assessment is shown in Figure 2. Quality-of-life forms were avail-
able for analysis at baseline for 227 out of 247 (92%) patients on
raltitrexed and 218 out of248 (88%) ofthosereceiving 5-FU + LV.
The numbers offorms available foranalysis are shown in Table 1.
Completion rates were lower at week 2 than at week 5; this may
have been because the week 2 assessment was added after a
protocol amendment, and some patients will have therefore been
missed early in the trial.
For the RSCL, analysis of covariance (ANCOVA) was used for
the 2-, 5-, 10- and 15-week assessments. Missing values were dealt
with in the same way as in study 3: if data existed for at least 50%
of the items in a dimension for a particular patient, the total score
for that dimension was scaled upproportionately. EuroQol contains
data in orderedcategories and was analysedby logistic regression.
At week 2, there were significant differences between
raltitrexed and 5-FU + LV in changes from baseline for all dimen-
sions and subdimensions of the RSCL, with the exception of the
psychological symptoms and disease categories, which fell just
outside the significance range. The statistically significant differ-
ences in favour of raltitrexed were: physical symptoms
P = 0.0001; activity levels P = 0.0114; and overall quality of life
P = 0.0001. The physical symptoms dimension of the RSCL was
further divided into symptoms specifically related to toxicity (sore
muscles, nausea and vomiting, diarrhoea, dizziness, tingling of
hands and feet, shivering, sore mouth or pain on swallowing, dry
mouth, burning or sore eyes and hair loss). Toxicity-related symp-
toms were significantly worse after the first treatment cycle (week
2, P = 0.0001) and over the treatment course (weeks 5 and 10) in
patients who received 5-FU + LV than in those who received
raltitrexed. For the period up to week 10 of treatment, raltitrexed
was consistently associated with significantly fewer toxicity-
related symptoms than 5-FU + LV.
The data from the EuroQol questionnaire indicated that, at week 2
(i.e. during cycle 1), there was a highly significant difference in
favour of raltitrexed in five of eight of the EuroQol dimensions
(Figure 3). Patients receiving raltitrexed were approximately
three times less likely to have problems with mobility and usual
activities than those randomized to 5-FU + LV (odds ratio 2.90,
P=0.0187 for mobility; odds ratio 3.09, P=0.0022 for usual
activities). They were also at least twice as likely to have a better
general health state (odds ratio 2.31, P = 0.0025), and there was a
suggestion that they were also two to three times as capable of self-
care as patients randomized to 5-FU + LV (odds ratio 2.49).
However, this effect was not statistically significant (P = 0.102). In
addition, at the same time point, the change from baseline in mean
health state and index was statistically significantly betterforpatients
receiving raltitrexed than for those receiving 5-FU + LV
(P = 0.0001 andP= 0.0455 respectively). Subsequently, these differ-
ences appeared to diminish but there were still some statistically non-
significant trends in favourofraltitrexed on the EuroQol scale and in
total symptom advantages that were maintained to week 10.
Those differences in the week 2 quality-of-life assessments in
favour of raltitrexed were perhaps not surprising when toxicity is
taken into account. Of the 5-FU + LV patients, 28.0% required
dosage reductions at cycle 2 because of toxicity. In contrast, only
4.4% ofpatients who received raltitrexed needed dosage reduction
(Figure 4). There was a statistically lower incidence of WHO
grade 3 and 4 mucositis in the raltitrexed than in the 5-FU + LV
group, with less WHO grade 3 and 4 diarrhoea and leucopenia
with raltitrexed. Liver transaminase rises were seen only in the
raltitrexed group, but these rises were of limited significance as
they were usually asymptomatic and self-limiting. The incidence
of all other WHO grade 3 and 4 toxicities was similar for both
treatments. The mean toxicity-related symptom scores at treatment
weeks 2, 5 and 10 are shown in Figure 5.
Surrogate end points for quality of life have also been collected.
Performance status of patients at study entry was documented.
WHO performance status was 0 in 121 (49.0%) patients receiving
raltitrexed and 106 (42.7%) of those receiving 5-FU + LV; 102
patients (41.3%) in the raltitrexed group and 125 patients (50.4%) in
the 5-FU + LV group had a performance status of 1; the rest had a
performance status of 2. Of patients with a baseline performance
status of 1 or 2, 37.4% ofthose who received raltitrexed and 31.8%
of those who received 5-FU + LV showed an improvement in
performance status (odds ratio 1.28, P =0.42). Weightgain occurred
in 13% of raltitrexed and 18.9% of 5-FU patients. Disease-related
symptoms improved in 86.1% and 83.1% of patients in the
raltitrexed (n = 115) and 5-FU (n = 124) groups respectively.
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DISCUSSION
Quality-of-life questionnaires must address disease-related symp-
toms and toxicities of the treatment under evaluation that have an
impact on quality of life. The questionnaire must be completed
frequently enough to detect difference, but should not be so much
of an imposition that the patient declines altogether to complete it.
In study 3, the questionnaire was administered too infrequently
to detect toxicity differences demonstrated early in the study. In
addition, it did not reflect the main toxicities associated with treat-
ment. Since the EORTC instrument was first issued, it has been
updated and developed to include disease-specific modules
(Aaronson et al, 1993). In the second study (study 12), the RSCL
and EuroQol were administered early enough to detect at the time
ofthe second course oftherapy the significant differences in toxi-
city that had necessitated dosage reduction for 28.0% of patients
treated with 5-FU + LV and 4.4% ofthose treated with raltitrexed.
Another problem concems the timing of quality-of-life ques-
tionnaires in relation to the administration of treatment. The
chemotherapy schedules in these studies were different, and the
quality-of-life questionnaires were completed at different times in
relation to chemotherapy administration and the onset of imme-
diate and late side-effects. Quality-of-life instruments should be
used early enough in the course of treatment to detect any differ-
ences in early toxicity. It is not clear with the tools available how
to compare a treatment given on 1 day every 3 weeks with a
regimen given for 5 consecutive days every 4-5 weeks.
The ideal frequency ofquality-of-life questionnaire administration
would be daily. Clearly, this would be a major imposition for the
patient, but it may be possible to design a simple diary card that
captures only data most liable to change. Gower and colleagues
(1995) have used this approach to show short-term changes inquality
of life that are related to acute symptoms induced by chemotherapy
thatwouldbe missedby less frequently administered measures. They
were able to identify a detrimental effect of a weekly regimen
compared with a 3-weekly regimen, with patients preferring the 3-
weekly regimen because ofless nausea and vomiting.
The occurrence of missing data is a frequent problem in studies
in which quality of life is being measured. The present studies
could have been biased through mechanisms that result in loss of
data (such as marked deterioration in quality of life in one or both
of the treatment arms), although there do not appear to be serious
biases in the results presented here. There are also the difficulties
associated with the management of missing values within a given
questionnaire: should the entire form be discounted ifone value is
missing, or can one or more values be imputed? What proportion
ofmissing values is it acceptable to impute?
Tumour progression impacts on quality of life, with deteriora-
tion in quality of life becoming apparent, or useful quality-of-life
data being lost because the patient is too ill to complete the ques-
tionnaire. The ways in which progression and death are handled
with reference to quality-of-life analysis may also affect conclu-
sions. In our analysis these factors were ignored.
Studies ofquality oflife may include a mixture of symptomatic
and asymptomatic patients. Asymptomatic patients are more likely
than those with symptoms to show reduced quality of life during a
study because of their developing disease-related symptoms
and/or signs of toxicity of therapy. Asymptomatic patients may
unbalance a quality-of-life analysis if two groups, one of which
contains more asymptomatic patients than the other, are compared.
When designing protocols involving quality-of-life end points,
consideration should be given to stratification ofsymptomatic and
asymptomatic patients at study entry.
For many years clinicians have used performance status,
changes in disease-related symptoms and toxicity to denote
changes in patients' quality of life. In reviewing quality-of-life
data from three major oncology journals, Batel-Copel et al (1997)
concluded that, although performance status was an important
measure, it was not adequate by itself to assess quality of life.
There remains a requirement for a simple instrument that is conve-
nient and easy for the patient to complete, but that measures
performance status, changes in disease-related symptoms and
toxicity, and the impact ofthese on the patient.
A tool to provide useful quality-of-life information in patients
with advanced colorectal cancer is currently being piloted. The
Chemotherapy Patient Monitor (CPM) consists of a checklist of
the most clinically relevant toxicities affecting patients with
advanced colorectal cancer, and gives an indication of the impact
oftreatment on patients. Patients are able to record the side-effects
that they have experienced since their previous visit, indicating
how troublesome these are and whether they wish to discuss them
with their physician. Diary cards are also available to enable
patients to make daily records between visits of side-effects. The
CPM could prove useful in ensuring consistency of communica-
tion between patients and health professionals. It may also lead to
more patient-centred treatment with improved patient satisfaction.
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